NCT05577364View on ClinicalTrials.gov

Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

February 28, 2026

Conditions
EBV-Positive Diffuse Large B-Cell Lymphoma, Nos
Interventions
DRUG

Selinexor

"Selinexor: 40mg qw po, and 60mg qw po (phase Ib); RP2D (II study);~Selinexor is added from the second cycle of R-CHOP regimen."

DRUG

R-CHOP Protocol

"Rituximab: 375mg/m2 iv.drip D1;~Cyclophosphamide: 750mg/m2 iv.drip D1;~Doxorubicin: 50mg/m2 iv.drip D1;~Vincristine: 1.4g/m2 iv D1;~Prednisone: 100mg po D1-5;"

Trial Locations (2)

51000

RECRUITING

Sun Yat-sen Universitiy Cancer Center, Guangzhou

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
collaborator

Fudan University

OTHER

collaborator

Antengene Corporation

INDUSTRY

lead

Sun Yat-sen University

OTHER